Document Detail


Current status of DILD in molecular targeted therapies.
MedLine Citation:
PMID:  23152005     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Molecular targeted drugs have become the mainstream for cancer therapy, and they have contributed to improving the outcome for cancer patients. On the other hand, molecular targeted drugs are associated with a variety of adverse drug reactions. Drug-induced interstitial lung disease (DILD) is a typical adverse drug reaction that has been an important problem with regard to safety management during cancer treatment. In the past, there was a lack of detailed and accurate epidemiological data about DILD. However, most of the molecular targeted drugs have been subject to all-case post-marketing surveillance since gefitinib-induced ILD became a concern. These surveillance data present useful information about DILD, such as frequency of adverse events, mortality, and risk factors, and as a result, the epidemiological profile of DILD associated with molecular targeted drugs has become apparent during the past decade. Further, it has been considered that the principal management for DILD is early detection and cessation of the suspected cause. However, ILD associated with everolimus and temsirolimus requires unusual management; i.e., patients with asymptomatic ILD are allowed to continue treatment with everolimus or temsirolimus, and even after symptomatic ILD, both everolimus and temsirolimus are allowed to be readministered after the resolution of ILD. As a result of the collected data, a change has begun in the field of DILD associated with molecular targeted drugs. The features of DILD can differ for each drug, and clinicians should thus keep this information about DILD in mind while treating patients.
Authors:
Yoshinobu Saito; Akihiko Gemma
Related Documents :
19494375 - Outbreak of hypoglycaemia: sexual enhancement products containing oral hypoglycaemic ag...
19711445 - Combined application of high resolution and tandem mass spectrometers to characterize m...
19589365 - Non-clinical post-marketing commitments for newly licenced pharmaceuticals.
10661745 - Collaboration between industry and academia--prospects for male fertility control.
15555485 - Impact of inappropriate drug use on health services utilization among representative ol...
17628445 - Inactivation of the miltefosine transporter, ldmt, causes miltefosine resistance that i...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-15
Journal Detail:
Title:  International journal of clinical oncology / Japan Society of Clinical Oncology     Volume:  -     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan, yo-saito@nms.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen ...
Next Document:  Regionally specific increased volume of the amygdala in Williams syndrome: Evidence from surface-bas...